(Reuters) - U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.
The Food and Drug Administration approved the once daily, long-acting basal insulin to treat adults with both type 1 and the far more prevalent type 2 diabetes.
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
15:02 U.S housing starts surge in December; jobless claims near 43-year low13
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High5
21:52 Netflix nears 94 million subscribers 10 years after streaming launch18